PERILS AND DILEMMAS OF THE INDISCRIMINATE USE OF GLP‑1 AGONISTS FOR AESTHETIC WEIGHT LOSS
DOI:
https://doi.org/10.61164/4bahhw68Keywords:
GLP-1 receptor agonists, Off-label use, Aesthetic complicationsAbstract
The indiscriminate use of GLP‑1 receptor agonists—such as semaglutide and liraglutide—originally developed to treat type 2 diabetes and obesity, has raised significant health concerns when used for aesthetic weight loss purposes without medical supervision. While these medications can lead to substantial weight loss, they are associated with common side effects like nausea, vomiting, diarrhea, and constipation. More serious risks include pancreatitis, gastroparesis, and intestinal obstruction. Additionally, rapid weight loss can result in muscle mass loss, particularly in individuals who do not engage in resistance exercises or consume adequate protein, potentially leading to osteoporosis. The unregulated use of these drugs has led to shortages, affecting patients who genuinely need them for medical conditions. Moreover, the promotion of such medications for aesthetic purposes can reinforce harmful beauty standards and stigmatize diverse body types. It's crucial that GLP‑1 receptor agonists be used only under medical supervision to ensure safety and efficacy.
Downloads
References
CARBONI, A.; WOESSNER, S.; MARTINI, O.; MARROQUIN, N. A.; WALLER, J. Natural weight loss or “Ozempic Face”: demystifying a social media phenomenon. Journal of Drugs in Dermatology, v. 23, n. 1, p. 1367–1368, Jan. 2024. DOI: 10.36849/JDD.7613.
DANESHGARAN, G.; SHAULY, O.; GOULD, D. J. “Ozempic Face” in Plastic Surgery: A Systematic Review of the Literature on GLP 1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions. Aesthetic Surgery Journal Open Forum, v. 7, o. ojaf056, 11 jun. 2025. DOI: 10.1093/asjof/ojaf056
CATANÉSE, L. C. GLP 1 diabetes and weight loss drug side effects: "Ozempic face" and more. Harvard Health Publishing, 5 fev. 2024. Disponível em: site da Harvard Health.
CATALFAMO, L.; DE PONTE, F. S.; DE RINALDIS, D. “Ozempic Face”: An Emerging Drug Related Aesthetic Concern and Its Treatment with Endotissutal Bipolar Radiofrequency (RF)—Our Experience. Journal of Clinical Medicine, v. 14, n. 15, 5269, 25 jul. 2025. DOI: 10.3390/jcm14155269.
TAO, J. M. D. The Ozempic Bod Gets Trimmer, ‘Ozempic Face’ Gets Older. Managed Healthcare Executive, 2024. Disponível em: site da MHE (AAO 2024). Acesso em: [data de acesso].
CLINICAL INSIGHT. “Ozempic Face”: What It Is and How To Avoid It. Cleveland Clinic, 5 mar. 2025. Disponível em: site da Cleveland Clinic. Acesso em: [data de acesso].
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Revista Multidisciplinar do Nordeste Mineiro
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish in this journal agree to the following terms:
Authors retain copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Creative Commons Attribution License, which permits the sharing of the work with proper acknowledgment of authorship and initial publication in this journal;
Authors are authorized to enter into separate, additional agreements for the non-exclusive distribution of the version of the work published in this journal (e.g., posting in an institutional repository or publishing it as a book chapter), provided that authorship and initial publication in this journal are properly acknowledged, and that the work is adapted to the template of the respective repository;
Authors are permitted and encouraged to post and distribute their work online (e.g., in institutional repositories or on their personal websites) at any point before or during the editorial process, as this may lead to productive exchanges and increase the impact and citation of the published work (see The Effect of Open Access);
Authors are responsible for correctly providing their personal information, including name, keywords, abstracts, and other relevant data, thereby defining how they wish to be cited. The journal’s editorial board is not responsible for any errors or inconsistencies in these records.
PRIVACY POLICY
The names and email addresses provided to this journal will be used exclusively for the purposes of this publication and will not be made available for any other purpose or to third parties.
Note: All content of the work is the sole responsibility of the author and the advisor.
